EUCTR2010-024264-18-IT进行中（未招募）1 期
A Single-Arm Multicenter Phase II Study preceded by Dose Evalua-tion to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
MICROMET GMBH0 个研究点目标入组 70 人开始时间: 2012年3月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Morphologic evidence of B-precursor ALL (pro B-, pre B-, common ALL) with > 25% blasts in bone marrow (M3) 2. Age < 18 years at enrollment [only children age 2-17 will be enrolled prior to the identification of the recommended Phase II dose]. 3. Relapsed/refractory disease: • Second or later bone marrow relapse, • Any marrow relapse after allogeneic HSCT, or • Refractory to other treatments: Patients in first relapse must have failed to achieve a CR following full standard reinduction chemotherapy regimen of at least 4 weeks duration Patients who have not achieved a first remission must have failed a full standard induction regimen 4. Karnofsky performance status = 50% for patients = 16 years and Lansky Performance Status (LPS) of = 50% for patients < 16 years 5. Organ function requirements: All patients must have a. Creatinine clearance = 70 mL/min/1.73 m2 or a normal serum creatinine based on age/gender b. Adequate liver function defined as: Total bilirubin = 1.5 x upper limit of normal (ULN) for age OR direct bilirubin = 1.5 mg/DL ALT (SGPT) = 135 IU/L 6. Patient and/or his/her legal representative have reviewed the patient information/informed consent form and have had their questions answered and have given written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 60
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Active acute or extensive chronic GvHD 2. Immunosuppressive agents to prevent or treat GvHD within 2 weeks prior to blinatumomab treatment 3. Evidence for current CNS involvement by ALL (CNS 2, CNS 3) or testicular involvement by ALL [patients with CNS relapse at the time of M3 relapse are not eligible for the Phase I part but are eligible for the Phase II part of the study, if CNS is successfully treated prior to enrollment]. Two successive CSF evaluations at least one week apart following completion of CNS therapy that are CNS1 are required 4. History of relevant CNS pathology or current relevant CNS pathology (seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) 5. History of autoimmune disease with potential CNS involvement or current autoimmune disease 6. Any HSCT within 3 months prior to blinatumomab treatment 7. Cancer chemotherapy within 2 weeks prior to blinatumomab treatment (except for intrathecal chemotherapy and/or low dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, glucocorticoids) 8. Chemotherapy related toxicities that haven’t resolved to = Grade 2 9. Radiotherapy within 4 weeks prior to blinatumomab treatment 10. Immunotherapy (e.g. rituximab, alemtuzumab) within 6 weeks prior to blinatumomab treatment 11. Any investigational product within 4 weeks prior to study entry 12. Known hypersensitivity to immune globulins or to any other component of the study drug formulation 13. Presence of HAMA reactivity (in patients with prior exposure to murine antibodies or proteins) 14. Active malignancy other than ALL 15. Active severe infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol An active infection is defined as: a. Positive blood culture within 48 hours of study enrollment b. Fever above 38.2 °C within 48 hours of study enrollment with clinical signs of infection 16. Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive) 17. Pregnant or nursing female adolescent patients 18. Post-menarchal female adolescent patients or male adolescent patients not willing to use an effective form of contraception during treatment phase of the study and at least 3 months thereafter. 19. Placed into an institution due to juridical or regulatory ruling
研究者
相似试验
进行中（未招募）
1 期
A Combined Pharmacokinetic, Dose-Finding, Safety and Efficacy Study in Pediatric and Adolescent Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Pediatric and adolescent patients with B-precursor ALL in second or later bone marrow relapse, in any marrow relapse after allogeneic HSCT, or refractory to other treatments.MedDRA version: 18.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2010-024264-18-NLAmgen Research (Munich) GmbH70
进行中（未招募）
1 期
A Combined Pharmacokinetic, Dose-Finding, Safety and Efficacy Study in Pediatric and Adolescent Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)EUCTR2010-024264-18-ATAmgen Research (Munich) GmbH70
进行中（未招募）
1 期
A Combined Pharmacokinetic, Dose-Finding, Safety and Efficacy Study in Pediatric and Adolescent Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Pediatric and adolescent patients with B-precursor ALL in second or later bone marrow relapse, in any marrow relapse after allogeneic HSCT, or refractory to other treatments.MedDRA version: 19.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2010-024264-18-DEAmgen Research (Munich) GmbH70
进行中（未招募）
1 期
A Combined Pharmacokinetic, Dose-Finding, Safety and Efficacy Study in Pediatric and Adolescent Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Pediatric and adolescent patients with B-precursor ALL in second or later bone marrow relapse, in any marrow relapse after allogeneic HSCT, or refractory to other treatments.MedDRA version: 17.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864EUCTR2010-024264-18-GBAmgen Research (Munich) GmbH93
进行中（未招募）
不适用
A Combined Pharmacokinetic, Dose-Finding, Safety and Efficacy Study in Pediatric and Adolescent Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)EUCTR2010-024264-18-Outside-EU/EEAAmgen Research (Munich) GmbH70